These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9709721)

  • 1. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease.
    Vernacchio L; Neufeld EJ; MacDonald K; Kurth S; Murakami S; Hohne C; King M; Molrine D
    J Pediatr; 1998 Aug; 133(2):275-8. PubMed ID: 9709721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
    Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
    J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
    Gaillat J
    Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis.
    Bjornson AB; Falletta JM; Verter JI; Buchanan GR; Miller ST; Pegelow CH; Iyer RV; Johnstone HS; DeBaun MR; Wethers DL; Wang WC; Woods GM; Holbrook CT; Becton DL; Kinney TR; Reaman GH; Kalinyak K; Grossman NJ; Vichinsky E; Reid CD
    J Pediatr; 1996 Dec; 129(6):828-35. PubMed ID: 8969724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia.
    Kaplan J; Sarnaik S; Schiffman G
    Am J Pediatr Hematol Oncol; 1986; 8(1):80-2. PubMed ID: 3717518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers.
    Pichichero ME; Shelly MA; Treanor JJ
    Pediatr Infect Dis J; 1997 Jan; 16(1):72-4. PubMed ID: 9002106
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of pneumococcal conjugate vaccines.
    Eskola J
    Pediatr Infect Dis J; 2000 Apr; 19(4):388-93. PubMed ID: 10783041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
    Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D
    Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
    PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
    J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.